Smith & Nephew (SN) Share Price, News & Analysis

Company Overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Key Stats

• Today's Range: 1,138.50 to 1,160
• 50-Day Range: 982.40 to 1,134
• 52-Week Range: N/A
• Volume: 2.85 million shs
• Average Volume: 343,671 shs
• Market Capitalization: £12.64 billion
• P/E Ratio: 41.51
• Dividend Yield: 3.66%
• Price Target: GBX 1,293.33
• Consensus Rating: Hold

Smith & Nephew Stock Analysis - MarketRank™

Smith & Nephew scored higher than 66% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Smith & Nephew has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 6 hold ratings, and no sell ratings.

Upside Potential

Smith & Nephew has a consensus price target of GBX 1,293.33, representing about 12.2% upside from its current price of GBX 1,153.

Amount of Analyst Coverage

Smith & Nephew has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Smith & Nephew is 41.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Smith & Nephew is 41.51, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.30.

Price to Earnings Growth Ratio

Smith & Nephew has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Smith & Nephew has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SN.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Smith & Nephew is a leading dividend payer. It pays a dividend yield of 3.66%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Smith & Nephew does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Smith & Nephew is 104.41%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Smith & Nephew has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

Search Interest

Only 27 people have searched for SN on MarketBeat in the last 30 days. This is a decrease of -4% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Smith & Nephew insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.19% of the stock of Smith & Nephew is held by insiders.

Percentage Held by Institutions

62.24% of the stock of Smith & Nephew is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:SN
• CIK: N/A
• Web: www.smith-nephew.com
• Phone: +44-20-74017646
• Fax: N/A
• Employees: 18,452
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Smith & Nephew: GBX 1,293.33
• High Price Target: GBX 1,600
• Low Price Target: GBX 1,000
• Potential Upside/Downside: +12.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 27.77
• Trailing P/E Ratio: 41.51
• Forward P/E Ratio: 12.41
• P/E Growth: 0.46
• Net Income: £382.79 million
• Net Margins: 10.08%
• Pretax Margin: N/A
• Return on Equity: 12.25%
• Return on Assets: 4.51%

Debt

• Debt-to-Equity Ratio: 73.07
• Current Ratio: 2.14
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: £7.08 billion
• Price / Sales: 1.79
• Cash Flow: GBX 61.71 per share
• Price / Cash Flow: 18.68
• Book Value: GBX 595.90 per share
• Price / Book: 1.93

Miscellaneous

• Outstanding Shares: 1,096,260,062
• Free Float: N/A
• Market Cap: £12.64 billion
• Optionable: Not Optionable
• Beta: 0.69